Komori
Share Issuance and Disposal4583Chiome Bioscience Inc.Pharmaceuticals

Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause)

A total of 14,251 of the 23rd Stock Acquisition Rights were exercised between 1 July and 21 July 2026, resulting in the delivery of 1,425,100 shares. The number of unexercised rights decreased from 29,235 to 14,984.

Worth reading
67In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1425100
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数1,425,100Shares

New shares: 1,425,100 shares

発行済株式総数

10.48% of the total number issued (shares exercised in this transaction)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The exercise prices on the respective exercise dates were ¥72.7, ¥70.9, ¥70.0, ¥72.7, ¥68.1, ¥67.2, ¥69.0 and ¥66.3. The lower limit under the adjustment clause is not disclosed.
Number of Stock Acquisition Rights
Total number issued: 135,984 rights (14,251 rights, or 10.48% of the total number issued). Unexercised rights as of the end of the previous month: 29,235; current unexercised rights: 14,984
Basis for determining the amount to be paid
With an exercise price adjustment clause. The exercise price on each exercise date is stated as ¥67.2–¥72.7, but the period used as the basis for the closing price and average share price, as well as the discount and premium rates, is not disclosed.
Most recent equity financing
Timing 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofNew shares: 1,425,100 shares
Dilution Rate10.48% of the total number issued (shares exercised in this transaction)
Total number of issued shares78,940,200 shares (as of the end of the previous month, including 22,819 treasury shares) → Not disclosed
Basis for determining the amount to be paidWith an exercise price adjustment clause. The exercise price on each exercise date is stated as ¥67.2–¥72.7, but the period used as the basis for the closing price and average share price, as well as the discount and premium rates, is not disclosed.
Exercise priceThe exercise prices on the respective exercise dates were ¥72.7, ¥70.9, ¥70.0, ¥72.7, ¥68.1, ¥67.2, ¥69.0 and ¥66.3. The lower limit under the adjustment clause is not disclosed.
Number of Stock Acquisition RightsTotal number issued: 135,984 rights (14,251 rights, or 10.48% of the total number issued). Unexercised rights as of the end of the previous month: 29,235; current unexercised rights: 14,984
Most recent equity financingTiming 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the status of the bulk exercise. No other reason is disclosed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chiome Bioscience Inc. (4583) timely disclosure | Komori